HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells

被引:129
作者
Shan, Meimei
Klasse, Per Johan
Banerjee, Kaustuv
Dey, Antu K.
Iyer, Sai Prasad N.
Dionisio, Robert
Charles, Dustin
Campbell-Gardener, Lila
Olson, William C.
Sanders, Rogier W.
Moore, John P. [1 ]
机构
[1] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 14850 USA
[2] Progen Pharmaceut Inc, Tarrytown, NY USA
[3] Univ Amsterdam, Acad Med Ctr, CINIMA, Dept Med Microbiol,Lab Expt Virol, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1371/journal.ppat.0030169
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 is a vaccine immunogen that can signal via several cell surface receptors. To investigate whether receptor biology could influence immune responses to gp120, we studied its interaction with human, monocyte-derived dendritic cells (MDDCs) in vitro. Gp120 from the HIV-1 strain JR-FL induced IL-10 expression in MDDCs from 62% of donors, via a mannose C-type lectin receptor(s) (MCLR). Gp120 from the strain LAI was also an IL-10 inducer, but gp120 from the strain KNH1144 was not. The mannose-binding protein cyanovirin-N, the 2G12 mAb to a mannose-dependent gp120 epitope, and MCLR-specific mAbs inhibited IL-10 expression, as did enzymatic removal of gp120 mannose moieties, whereas inhibitors of signaling via CD4, CCR5, or CXCR4 were ineffective. Gp120-stimulated IL-10 production correlated with DC-SIGN expression on the cells, and involved the ERK signaling pathway. Gp120-treated MDDCs also responded poorly to maturation stimuli by up-regulating activation markers inefficiently and stimulating allogeneic T cell proliferation only weakly. These adverse reactions to gp120 were MCLR-dependent but independent of IL-10 production. Since such mechanisms might suppress immune responses to Env-containing vaccines, demannosylation may be a way to improve the immunogenicity of gp120 or gp140 proteins.
引用
收藏
页码:1637 / 1650
页数:14
相关论文
共 87 条
[1]   Analysis of IGG and IGG4 in HIV-1 seropositive patients and correlation with biological and genetic markers [J].
Abbas, A ;
Vasilescu, A ;
Do, H ;
Hendel, H ;
Maachi, M ;
Goutalier, FX ;
Regulier, EG ;
Rappaport, J ;
Matsuda, F ;
Therwath, A ;
Aucouturier, P ;
Zagury, JF .
BIOMEDICINE & PHARMACOTHERAPY, 2005, 59 (1-2) :38-46
[2]   EXPRESSION AND CHARACTERIZATION OF CD4-IGG(2), A NOVEL HETEROTETRAMER THAT NEUTRALIZES PRIMARY HIV TYPE-1 ISOLATES [J].
ALLAWAY, GP ;
DAVISBRUNO, KL ;
BEAUDRY, GA ;
GARCIA, EB ;
WONG, EL ;
RYDER, AM ;
HASEL, KW ;
GAUDUIN, MC ;
KOUP, RA ;
MCDOUGAL, JS ;
MADDON, PJ .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (05) :533-539
[3]  
AMEGLIO F, 1994, CLIN EXP IMMUNOL, V95, P455, DOI 10.1111/j.1365-2249.1994.tb07018.x
[4]   Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A [J].
Beddows, Simon ;
Kirschner, Marc ;
Campbell-Gardener, Lila ;
Franti, Michael ;
Dey, Antu K. ;
Iyer, Sai Prasad N. ;
Maddon, Paul J. ;
Paluch, Maciej ;
Master, Aditi ;
Overbaugh, Julie ;
VanCott, Thomas ;
Olson, William C. ;
Moore, John P. .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (06) :569-579
[5]   Endocytosis of HIV-1 activates plasmacytoid dendritic cells via toll-like receptor-viral RNA interactions [J].
Beignon, AS ;
McKenna, K ;
Skoberne, M ;
Manches, O ;
DaSilva, I ;
Kavanagh, DG ;
Larsson, M ;
Gorelick, RJ ;
Lifson, JD ;
Bhardwaj, N .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (11) :3265-3275
[6]   INDUCTION OF INTERLEUKIN-10 BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND ITS GP120 PROTEIN IN HUMAN MONOCYTES MACROPHAGES [J].
BORGHI, P ;
FANTUZZI, L ;
VARANO, B ;
GESSANI, S ;
PUDDU, P ;
CONTI, L ;
CAPOBIANCHI, MR ;
AMEGLIO, F ;
BELARDELLI, F .
JOURNAL OF VIROLOGY, 1995, 69 (02) :1284-1287
[7]   Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides [J].
Botos, I ;
O'Keefe, BR ;
Shenoy, SR ;
Cartner, LK ;
Ratner, DM ;
Seeberger, PH ;
Boyd, MR ;
Wlodawer, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (37) :34336-34342
[8]   Interleukin-10 determines viral clearance or persistence in vivo [J].
Brooks, David G. ;
Trifilo, Matthew J. ;
Edelmann, Kurt H. ;
Teyton, Luc ;
McGavern, Dorian B. ;
Oldstone, Michael B. A. .
NATURE MEDICINE, 2006, 12 (11) :1301-1309
[9]   Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: Poorer control of a pathogenic viral challenge [J].
Buge, SL ;
Ma, HL ;
Amara, RR ;
Wyatt, LS ;
Earl, PL ;
Villinger, F ;
Montefiori, DC ;
Staprans, SI ;
Xu, Y ;
Carter, E ;
O'Neil, SP ;
Herndon, JG ;
Hill, E ;
Moss, B ;
Robinson, HL ;
McNicholl, JM .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2003, 19 (10) :891-900
[10]   HIV vaccine design and the neutralizing antibody problem [J].
Burton, DR ;
Desrosiers, RC ;
Doms, RW ;
Koff, WC ;
Kwong, PD ;
Moore, JP ;
Nabel, GJ ;
Sodroski, J ;
Wilson, IA ;
Wyatt, RT .
NATURE IMMUNOLOGY, 2004, 5 (03) :233-236